Literature DB >> 8248852

Distinct kinetic binding properties of N-[3H]-methylscopolamine afford differential labeling and localization of M1, M2, and M3 muscarinic receptor subtypes in primate brain.

D D Flynn1, D C Mash.   

Abstract

Three classes of muscarinic receptors in mammalian brain have been postulated on the basis of equilibrium and kinetic binding data. However, equilibrium binding assays alone have not permitted a clear demonstration of the localization of putative M1, M2, and M3 receptor subtypes in the brain because of the overlapping affinities of virtually all muscarinic antagonists. In the present study, the conditions for selective occupancy of the M1, M2, and M3 receptor subtypes in the brain of the rhesus monkey were based on the distinct kinetic and equilibrium binding properties of N-[3H]-methylscopolamine (NMS) at cloned m1-m4 muscarinic receptor subtypes expressed in A9L transfected cells. Quantitative autoradiography of the M1, M2, and M3 muscarinic receptor subtypes in the primate brain was performed according to the following strategy. The M1 (m1) receptor subtype was labeled directly with a non-saturating concentration of [3H]-pirenzepine. The M2 (m2) subtype was labeled by incubations consisting of short, two minute pulses of [3H]-NMS after a preincubation with 0.3 microM pirenzepine to occlude m1, m3, and m4 sites. Selective occupancy of the M3 (m3) receptor (subtype) was achieved by pre-incubation with 0.5 nM unlabeled NMS to partially occlude the m1, m2, and m4 sites, equilibrium with 0.5 nM [3H]-NMS, followed by a 60 minute tracer dissociation in the presence of 1 microM atropine. In vitro autoradiography demonstrated that the M1 receptor subtype was confined to forebrain structures. M1 receptors were prevalent throughout the cerebral cortical mantle, amygdala, hippocampus, and the striatum. Low to background levels of the M1 receptor subtype were measured over the thalamus, hypothalamus, and brainstem. The M2 subtype was widely distributed with elevated densities of binding sites seen over all primary sensory cortical areas, and within discrete thalamic, hypothalamic, and brainstem nuclei. The distribution of the M3 receptor subtype was largely coincident with the pattern of the M1 sites labeled by non-saturating concentrations of [3H]-pirenzepine with some notable exceptions. Within the cerebral cortical mantle, the M3 receptor exhibited an elevated gradient over the orbitofrontal gyrus and the temporal lobe. Within the striatum, the M3 subtype was elevated over the anterior and dorsal part of the caudate nucleus, while the M1 receptors were most prevalent over the ventromedial sector. Selective labeling of M3 receptors was seen over the medial division of the globus pallidus and within the substantia nigra pars reticulata. In contrast to the pattern of the M1 receptor subtype, M3 receptors were prevalent also over midline nuclei of the hypothalamus.(ABSTRACT TRUNCATED AT 400 WORDS)

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8248852     DOI: 10.1002/syn.890140406

Source DB:  PubMed          Journal:  Synapse        ISSN: 0887-4476            Impact factor:   2.562


  11 in total

1.  Why does the agonist [(18)F]FP-TZTP bind preferentially to the M(2) muscarinic receptor?

Authors:  L Ravasi; D O Kiesewetter; K Shimoji; G Lucignani; W C Eckelman
Journal:  Eur J Nucl Med Mol Imaging       Date:  2005-12-07       Impact factor: 9.236

Review 2.  Cholinergic interneurons in the dorsal and ventral striatum: anatomical and functional considerations in normal and diseased conditions.

Authors:  Kalynda K Gonzales; Yoland Smith
Journal:  Ann N Y Acad Sci       Date:  2015-04-15       Impact factor: 5.691

Review 3.  Oxidative stress and inflammation in brain aging: nutritional considerations.

Authors:  J A Joseph; B Shukitt-Hale; G Casadesus; D Fisher
Journal:  Neurochem Res       Date:  2005 Jun-Jul       Impact factor: 3.996

4.  Effects of typical and atypical antipsychotic drugs on rat brain muscarinic receptors.

Authors:  Katerina Zavitsanou; Vu H Nguyen; Mei Han; Xu Feng Huang
Journal:  Neurochem Res       Date:  2007-03       Impact factor: 3.996

5.  Brain muscarinic receptors in progressive supranuclear palsy and Parkinson's disease: a positron emission tomographic study.

Authors:  M Asahina; T Suhara; H Shinotoh; O Inoue; K Suzuki; T Hattori
Journal:  J Neurol Neurosurg Psychiatry       Date:  1998-08       Impact factor: 10.154

6.  Comparison of the pharmacokinetics of different analogs of 11C-labeled TZTP for imaging muscarinic M2 receptors with PET.

Authors:  Alicia E Reid; Yu-Shin Ding; William C Eckelman; Jean Logan; David Alexoff; Colleen Shea; Youwen Xu; Joanna S Fowler
Journal:  Nucl Med Biol       Date:  2008-04       Impact factor: 2.408

7.  Differential kinetics of [123I]beta-CIT binding to dopamine and serotonin transporters.

Authors:  M Fujita; K Takatoku; Y Matoba; M Nishiura; K Kobayashi; O Inoue; T Nishimura
Journal:  Eur J Nucl Med       Date:  1996-04

8.  Autoradiography of 3H-pirenzepine and 3H-AFDX-384 in Mouse Brain Regions: Possible Insights into M1, M2, and M4 Muscarinic Receptors Distribution.

Authors:  Paulina Valuskova; Vladimir Farar; Sandor Forczek; Iva Krizova; Jaromir Myslivecek
Journal:  Front Pharmacol       Date:  2018-02-20       Impact factor: 5.810

9.  [11C]AF150(S), an agonist PET ligand for M1 muscarinic acetylcholine receptors.

Authors:  Hans Jc Buiter; Albert D Windhorst; Marc C Huisman; Maqsood Yaqub; Dirk L Knol; Abraham Fisher; Adriaan A Lammertsma; Josée E Leysen
Journal:  EJNMMI Res       Date:  2013-03-21       Impact factor: 3.138

10.  The structural study of mutation-induced inactivation of human muscarinic receptor M4.

Authors:  Jingjing Wang; Meng Wu; Lijie Wu; Yueming Xu; Fei Li; Yiran Wu; Petr Popov; Lin Wang; Fang Bai; Suwen Zhao; Zhi-Jie Liu; Tian Hua
Journal:  IUCrJ       Date:  2020-02-22       Impact factor: 4.769

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.